Adding Electronics to Drug Delivery Devices: Satisfying the Needs of Patients, Healthcare Professionals and Regulators
ERS International Congress 2022
Sunday, September 4 | 12:00 - 12:45 PM CET
Yury Rozenman. SVP of Business Development, Propeller Health
Emilia Kruzel. Sr. Manager of Strategic Partnerships, Propeller Health
Join us for an exclusive session you won’t want to miss! Seats are limited and filling up quickly. Light refreshments will be served.
Connected drug delivery devices are increasingly being developed to support improved medication adherence, patient supervision, and remote monitoring in home-care settings. In patients with asthma and chronic obstructive pulmonary disease (COPD), non-adherence to all therapies is associated with poor disease control, reduced quality of life, increased exacerbations, and increased healthcare utilization.
Propeller Health has been at the forefront of connecting respiratory medications, empowering patients to self-manage, enabling care teams with objective patient data, and improving patient outcomes. For more than a decade, we have worked closely with several of the world’s leading pharmaceutical companies to deliver these solutions first-hand, experiencing successes and overcoming challenges along the way.
During this session, we will explore these valuable lessons and discuss what to do (or what not to do) in order to develop a connected care experience that supports patients and their doctors in generating better outcomes across the care continuum.
Note: Please ensure that you are registered to attend the ERS International Congress 2022.
At Propeller, we believe everyone can breathe better in a world where chronic disease is predictable, preventable, and manageable. Propelled by our roots in public health, we are a precision digital health company powering motivating, care-connected patient journeys that uplift lives and unify value for all participants in healthcare around the world. As a wholly owned subsidiary of ResMed, Propeller brings broad respiratory care expertise, digital therapeutic coverage, and scale globally.